Download Files:
Burixafor (hydrobromide)
$100 – $2,200
Products Details
Product Description
– Burixafor hydrobromide (TG-0054 hydrobromide) is an orally bioavailable and potent antagonist of CXCR4 and a well anti-angiogenic drug that is of potential value in treating choroid neovascularization[1]. Burixafor hydrobromide (TG-0054 hydrobromide) mobilizes mesenchymal stem cells, attenuates inflammation, and preserves cardiac systolic function in a porcine model of myocardial infarction[2].
Web ID
– HY-19867A
Storage Temperature
– -20°C (Powder, stored under nitrogen)
Shipping
– Blue Ice
Applications
– COVID-19-immunoregulation
Molecular Formula
– C27H51N8O3P.5/2HBr
References
– [1]Shelke NB, et al. Intravitreal Poly(L-lactide) Microparticles Sustain Retinal and Choroidal Delivery of TG-0054, a Hydrophilic Drug Intended for Neovascular Diseases. Drug Deliv Transl Res. 2011 Feb;1(1):76-90.|[2]Hsu WT, et al. CXCR4 Antagonist TG-0054 Mobilizes Mesenchymal Stem Cells, Attenuates Inflammation, and Preserves Cardiac Systolic Function in a Porcine Model of Myocardial Infarction. Cell Transplant. 2015;24(7):1313-28.
CAS Number
– 1191450-19-7
Molecular Weight
– 769.01
Compound Purity
– 98.0
SMILES
– NC1=CC(N2CCN(CCP(O)(O)=O)CC2)=NC(NC[C@H]3CC[C@H](CNCCCNC4CCCCC4)CC3)=N1.[H]Br.[5/2]
Clinical Information
– Phase 2
Research Area
– Inflammation/Immunology; Cardiovascular Disease; Endocrinology; Cancer
Solubility
– H2O : 50 mg/mL (ultrasonic)
Target
– CXCR
Isoform
– CXCR4
Pathway
– GPCR/G Protein;Immunology/Inflammation
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
